First‐in‐human assessment of safety and pharmacokinetics of EP9001A:an anti‐nerve growth factor antibody for chronic pain treatment
The dose-dependent pharmacokinetics and long half-life suggest the possibility of longer dosing intervals. Future trials should optimise dosing and evaluate long-term safety, particularly with respect to adverse musculoskeletal events arising through inhibition of nerve growth factor.
Authors
- Ping Feng (ORCID: https://orcid.org/0000-0001-5488-0814)
- Siyu Li (ORCID: https://orcid.org/0000-0002-0027-5296)
- Man Chen (ORCID: https://orcid.org/0000-0001-7030-9968)
- Yue Cheng (ORCID: https://orcid.org/0000-0003-4697-4081)
- Xiaohong Zhu
- Qingqing Li
- Shuang Li
- Ye Wang
- Feiyan Zeng
- Qiao Yan
Institutions
- National Medical Products Administration (CN)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-12-30
- DOI
- https://doi.org/10.1111/bph.70317
- Primary Topic
- Pain Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00